Is Your Hospice Pharmacy PPD Really All In?

Hospice Pharmacy PPD Should Be Verifiable Not Just Reported

A hospice pharmacy per patient per day figure is only useful when leadership can see what the number includes, how it was calculated, and what caused it to change. A low-looking PPD may leave out dispensing fees, pharmacy benefit management fees, transaction charges, or other pharmacy costs. A higher PPD may reflect patient acuity or clinically necessary utilization rather than poor performance. The number needs context.

For hospice leaders, the practical question is not simply, “What is our PPD?” It is, “Can we verify our all-in pharmacy spend and explain the result?” That distinction matters because Medicare generally pays hospice providers a daily rate for covered services in the plan of care, including drugs used for pain and symptom management. Pharmacy cost variability therefore affects budgeting, forecasting, and the resources available to support care.

A transparent pharmacy model should make each major cost component visible, connect spending to utilization, and establish clear accountability when results do not match expectations. The following questions help hospice leaders evaluate whether their current arrangement provides that level of control.

Key Takeaways

All-in PPD should include medication costs and every related pharmacy, PBM, dispensing, and transaction fee.
Hospice leaders should be able to verify medication pricing and trace changes to utilization, pricing, or fees.
A PPD benchmark is a prompt for investigation, not a diagnosis by itself.
Useful reporting should identify costs by medication, patient, and fee type without requiring leaders to assemble multiple files.
Transparency is strongest when it is paired with clinical education, defined service standards, and one accountable partner.

What Is All In Pharmacy PPD

All-in pharmacy PPD is total pharmacy-related spend for a defined period divided by the total number of patient days in that same period. It should include medication costs, pharmacy dispensing fees, PBM administrative fees, transaction fees, and any other charges connected to the pharmacy benefit.

Total all-in pharmacy spend / Total patient days = All-in pharmacy PPD

The period and numerator must match. If a hospice uses monthly spend, it should use patient days from that same month. Leaders should also know whether reversals, credits, rejected transactions, urgent deliveries, special packaging, or other adjustments are reflected. Otherwise, the organization may be comparing unlike figures across months or vendors.

MaxHaven recommends reviewing PPD monthly to spot changes and evaluating performance more fully each quarter. The monthly view can surface an unusual increase. The quarterly view provides enough context to examine whether the change came from patient mix, medication utilization, contract pricing, or fees.

Why Can Two PPD Figures Tell Different Stories

PPD is not automatically an apples-to-apples comparison. One provider may report medication ingredient cost only. Another may include dispensing and administrative charges. A third may combine several categories but exclude transaction fees or ancillary services. Each number may be calculated correctly under its own definition while still producing a misleading comparison.

Utilization also matters. A change in census does not affect every pharmacy cost in the same way, and two hospices with similar census may serve patients with different diagnoses, acuity, lengths of stay, or medication needs. Clinically appropriate use of a higher-cost therapy can raise PPD without indicating poor management. Conversely, a low headline PPD can conceal separate charges elsewhere in an invoice.

This is why cost transparency requires more than a benchmark. Leadership needs a consistent definition, access to the underlying detail, and a process for investigating variance without compromising patient-centered care.

Seven Questions to Ask About Your Current Pharmacy Model

1. What Costs Are Included in Our PPD

Ask for the exact numerator used in the calculation. It should be possible to identify medication costs, dispensing fees, PBM fees, transaction charges, delivery or packaging charges when applicable, credits, and other pharmacy-related expenses.

If the answer is simply “drug spend,” ask what appears elsewhere. A PPD that excludes material charges does not give leadership a complete view of the pharmacy model.

Which charges are included and excluded?
Are fees shown separately or embedded in medication pricing?
Are reversals and credits reflected in the same reporting period?

2. Can We Verify What Medications Are Supposed to Cost

Hospice leaders should understand the pricing benchmark in the contract and be able to verify how it applies. NADAC, or National Average Drug Acquisition Cost, is a CMS-published benchmark based on pharmacy acquisition-cost survey data. Because the data is publicly available, it can give organizations a reference point for reviewing medication pricing.

No benchmark answers every question on its own. Leaders should also understand the method used when a medication does not have a NADAC value, the amount and purpose of administrative or dispensing fees, and whether the PBM retains a spread between what it pays the pharmacy and what it charges the hospice.

What benchmark determines the medication price?
What happens when that benchmark is unavailable?
Can we reproduce the calculation from the contract and claim detail?

3. What Is Driving Changes in Our PPD

A useful report should help leaders separate pricing effects from utilization effects. Contract terms and pricing methodology can change the amount paid for the same medication. Utilization can change because of patient needs, prescribing patterns, quantities dispensed, dosage forms, or the use of clinically appropriate formulary alternatives.

The goal is not to second-guess individual clinical decisions from a finance report. It is to identify patterns that deserve collaborative review by clinical, pharmacy, operations, and finance leaders. When those teams can see the same information, they can ask better questions while keeping comfort, dignity, and the plan of care at the center.

4. Does What the Hospice Pays Match How the Pharmacy Is Reimbursed

A meaningful warning sign is a discrepancy between what the pharmacy receives and what the hospice is charged. That difference may reflect disclosed fees or other contract terms, but leadership should be able to identify and explain it.

Ask whether the arrangement uses spread pricing, pass-through pricing, or another structure. Then request enough claim and remittance detail to reconcile the amounts. Transparency means the difference is visible and contractually understandable, not merely that a report lists a total.

5. How Quickly Can We See and Investigate the Data

A report that arrives long after the close of a month may confirm a problem without giving the hospice time to respond. Ask how often data refreshes, when claims become visible, and how corrections or reversals appear.

Timely information supports earlier investigation, but speed should not be confused with completeness. Leadership needs current data that includes the relevant fees and can be reconciled to invoices. A dashboard is useful when it reduces manual work and makes the underlying cost drivers easier to understand.

6. Can We Review Costs by Medication Patient and Fee Type

A single total can show that spend changed, but not why. Leaders should be able to move from the organization-level number to the categories that explain it. At a minimum, reporting should support review by medication, patient, and fee type when permitted and appropriate for the user’s role.

That detail can help identify a medication outlier, a change in utilization, an unexpected ancillary charge, or a recurring process issue. Access should follow applicable privacy and security requirements, with the right information available to authorized clinical, financial, and operational users.

7. Who Is Accountable When Pricing or Service Falls Short

Cost transparency is incomplete without operational accountability. Hospice pharmacy performance also depends on medication access, after-hours processes, delivery coordination, communication, escalation, and consistent application of contract terms.

Hospice leaders should know which service standards apply, how performance is measured, and who owns resolution when the pharmacy, PBM, or another party misses an expectation. A fragmented model can leave staff coordinating among several vendors while no single partner owns the outcome.

Are service expectations documented and measurable?
Who investigates pricing or service discrepancies?
What is the escalation path, and how is resolution tracked?

What Warning Signs Deserve a Closer Review

No single number proves that a pharmacy arrangement is working well or poorly. Still, several signals should prompt a structured review:

An all-in PPD above $9. MaxHaven uses this as a review trigger based on its client and industry experience. It should start an investigation, not serve as proof of overcharging or inappropriate utilization.
A reported PPD that does not include dispensing, administrative, transaction, or other pharmacy-related fees.
A material change in PPD that the provider cannot connect to pricing, utilization, patient mix, or another documented cause.
A difference between pharmacy reimbursement and the hospice charge that cannot be readily explained from the contract and claim detail.
Reports that require leaders to combine multiple spreadsheets or invoices before they can understand total spend.
No clear owner for resolving pricing discrepancies, service failures, or repeated exceptions.

The appropriate response is not automatic cost cutting. It is disciplined review. Leaders should examine the data with clinical and pharmacy partners, distinguish necessary patient care from avoidable variation, and decide whether the current arrangement provides enough visibility and control.

What Does MaxHaven Do Differently

MaxHaven is designed as a hospice pharmacy partnership rather than a traditional PBM-only arrangement. Its model connects transparent pricing, business intelligence, clinical education, pharmacy service standards, and centralized accountability.

Medication pricing begins with NADAC when a NADAC value is available. When it is not, MaxHaven uses an estimated acquisition cost methodology, followed by an AWP-based method when the applicable National Drug Code has neither NADAC nor estimated acquisition cost pricing. The purpose of a defined hierarchy is to make the pricing basis understandable instead of leaving leadership with an unexplained final charge.

The MaxHaven Data Analytics Dashboard updates nightly, so information is no more than 24 hours old. Authorized leaders can review pharmacy spend by medication, patient, and fee type on one page rather than gathering several files. This visibility helps teams identify what changed and begin the right clinical, operational, or financial conversation.

MaxHaven was built by pharmacists on a foundation of transparency and clinical education. That clinical perspective matters because responsible pharmacy management is not simply a search for the least expensive medication. It requires patient-specific decisions, clinically appropriate formulary alternatives, reliable service, and a clear connection between care needs and financial stewardship.

The larger distinction is accountability. MaxHaven aligns the hospice, pharmacy, and pharmacy benefit functions around defined expectations and ongoing performance oversight. Hospice leaders gain one partner responsible for helping make pricing, utilization, service performance, and exceptions visible and actionable.

A Better PPD Conversation Starts With Better Questions

PPD should help hospice leaders make decisions, not merely give them another number to report. An all-in calculation, a verifiable pricing method, timely detail, and clear ownership turn PPD into a practical management tool. Without those elements, even an attractive benchmark can leave important costs and risks unexplained.

Start by asking your current pharmacy or PBM what is included, how medication prices can be verified, why PPD changes, and who is accountable when performance falls short. If those answers require several vendors, several files, or several different definitions, the model may not provide the control leadership needs.

Knowing your PPD is only the starting point. Hospice leaders also need to understand how their costs compare and what is driving changes in pharmacy spend. A complimentary MaxHaven Hospice Pharmacy Price Analysis can provide a clearer view of your current pharmacy model.

Know Your PPD. Know Your Market. Know What’s Driving It.

Request Your Complimentary MaxHaven Price Analysis.

Frequently Asked Questions

What does PPD mean in hospice pharmacy?

PPD means per patient per day. An all-in pharmacy PPD divides total pharmacy-related spend for a defined period by total patient days in that same period.

What costs should be included in hospice pharmacy PPD?

An all-in calculation should include medication costs, pharmacy dispensing fees, PBM administrative fees, transaction fees, and other pharmacy-related charges. The organization should document any exclusions.

How often should hospice leaders review pharmacy PPD?

MaxHaven recommends monitoring PPD monthly and completing a fuller evaluation quarterly. Monthly review helps identify movement, while quarterly review provides more context for pricing, utilization, and patient-mix changes.

Is a high PPD always a sign of poor pharmacy performance?

No. PPD can rise because of clinically necessary utilization, patient acuity, medication mix, quantities, pricing, or fees. A higher number is a reason to investigate, not a conclusion by itself.

How can a hospice verify medication pricing?

Leaders should know the contract benchmark, confirm how it applies at the claim level, understand the fallback when the primary benchmark is unavailable, and identify every administrative or dispensing fee.

What does pharmacy cost transparency look like?

Transparency means leadership can trace the total charge to medication pricing, utilization, and disclosed fees; reconcile what the hospice pays; and identify who is responsible for resolving discrepancies.

What should hospice leaders ask a pharmacy benefit partner?

Ask what is included in PPD, how medication prices are verified, how often data updates, what reporting detail is available, whether spread pricing exists, which service standards apply, and who owns issue resolution.